# DCC

Source: https://onco.cc/targets/dcc/  
OnCo record `dcc` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DCC (Netrin receptor DCC) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Hepatocellular carcinoma and 3 more.

## Summary

Receptor for netrin required for axon guidance. Mediates axon attraction of neuronal growth cones in the developing nervous system upon ligand binding. Its association with UNC5 proteins may trigger signalling for axon repulsion.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.59 (direct and indirect evidence; datatypes literature 0.87, animal model 0.70, genetic association 0.62, somatic mutation 0.63). IntOGen calls it a driver in 5 cohorts (2 activating, 3 loss-of-function), covering Colorectal Adenocarcinoma, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, Prostate Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: DCC netrin 1 receptor; Netrin receptor DCC; IGDCC1; NTN1R1
- Tags: cancer-genes-wave
- Symbol: DCC
- Class: tumor-suppressor
- Biology: Receptor for netrin required for axon guidance. Mediates axon attraction of neuronal growth cones in the developing nervous system upon ligand binding. Its association with UNC5 proteins may trigger signalling for axon repulsion. It also acts as a dependence receptor required for apoptosis induction when not associated with netrin ligand. Implicated as a tumour suppressor gene. Location: Membrane (UniProt). Locus 18q21.2 (HGNC).
- Where found: Colorectal cancer: Open Targets association 0.51 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease; Oesophageal cancer: IntOGen driver in 1 cohort (ESCA); Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC); Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD); Prostate cancer: IntOGen driver in 1 cohort (PRAD); Oesophageal and junctional adenocarcinoma: IntOGen driver in 1 cohort (ESCA)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:2701: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2701
- UniProt P43146: https://www.uniprot.org/uniprotkb/P43146/entry
- NCBI Gene 1630: https://www.ncbi.nlm.nih.gov/gene/1630
- Ensembl ENSG00000187323: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187323

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Oesophageal and junctional adenocarcinoma](https://onco.cc/cancers/oesophageal-adenocarcinoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- pathways: [Colorectal cancer (KEGG map)](https://onco.cc/pathways/colorectal-cancer-signalling/)
- trials: [A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)](https://onco.cc/trials/nct06630234/), [A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies](https://onco.cc/trials/nct05957367/), [Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor](https://onco.cc/trials/nct03069469/)

---
JSON: https://onco.cc/api/v1/entities/dcc.json